Overview

Tiotropium and Salmeterol PK Study in COPD Patients

Status:
Completed
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
The primary objective of this study is to characterize the pharmacokinetics (i.e. systemic exposure to tiotropium and salmeterol) of tiotropium qd + salmeterol qd or bid versus tiotropium qd and salmeterol bid following 4-week treatment periods in patients with chronic obstructive pulmonary disease (COPD).
Phase:
Phase 3
Details
Lead Sponsor:
Boehringer Ingelheim
Treatments:
Salmeterol Xinafoate
Tiotropium Bromide